RadNet, Inc. (RDNT) Stock: Price, Forecast & Analyst Target
RadNet, Inc. (RDNT) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $69.51 (-3.22%), as of the Nov 19, 2026 trading session; market cap $5.48B.
Educational signal · not a buy or sell recommendation · How to read this
RadNet, Inc. · RDNT · NASDAQ · Healthcare · Diagnostics & Research
Research dated 2026-09-13: RadNet operates a network of outpatient diagnostic imaging centers across the United States, offering MRI, CT, PET, mammography, and other advanced imaging services. The key question for investors is whether RadNet can grow volumes and pricing power in a market where consolidation is accelerating and payment rates are compressing.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · RadNet (RDNT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — a fragile balance sheet underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $623M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 3 of the last 8 reports
- Altman Z 1.95 · Piotroski F 3
Holding back: balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 37 | Weak | |
| 37 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $69.51 | |
| Change on the day | -3.22% | |
| 52-week range | $50.82–$85.84 | |
| Market capitalisation | $5.48B | — |
| Shares traded on the day | 747.8K | |
| Beta (volatility vs the S&P 500) | 1.4 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for RadNet (RDNT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is RadNet (RDNT), and what does it report?
Short answer · as of
RadNet is a healthcare services operator—not a medical device maker, not a staffing agency. Revenue comes from imaging procedures performed at owned or managed centers.
Research dated 2026-09-13.
What drives the numbers is patient volume, average revenue per procedure, and labor costs relative to revenue.
What do the latest results show for RadNet (RDNT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $623M.
Research dated 2026-09-13.
Revenue grew in the latest quarter compared to the prior-year period, and the company swung to a small profit after losses in the preceding quarter. The turnaround suggests either better operating discipline, higher patient volume, or favorable mix shift toward higher-margin procedures.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $623M | $8M | $0.10 (diluted) |
| Q1 FY2026 | $576M | -$33M | -$0.43 (diluted) |
| Q4 FY2025 | $548M | -$597,000 | -$0.01 (diluted) |
| Q3 FY2025 | $523M | $5M | $0.07 (diluted) |
What are the financial strengths and risks for RadNet (RDNT)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The balance sheet carries substantial debt relative to equity and market value. Operating cash flow is positive despite negative net income in prior quarters, a sign that the company generates cash but has high capital requirements. The principal risk is payment rate compression from insurance companies and shifts in payer mix toward lower-paying programs.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at RadNet (RDNT)?
Short answer · as of
Current published price targets run low $65.00 · high $95.00 · consensus $80.00 · median $80.00 against a quoted price of $69.51 (as of Nov 19, 2026).
Research dated 2026-09-13.
Upcoming reports should show whether procedure volumes are sustaining in the face of economic weakness and whether the company is gaining or losing market share in key metro areas. Watch for commentary on reimbursement rates and payer mix, as commercial insurance reimbursement exceeds government program rates significantly.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does RadNet compare with its peers?
Short answer
RadNet's score ranks 6th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
RadNet differs from hospital-based imaging by focusing on outpatient centers, which have lower overhead and faster patient throughput. However, hospital consolidation is reducing the universe of independent centers RadNet can acquire at reasonable prices.
| Company | Price | Market value | Score |
|---|---|---|---|
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $64.02 Nov 19, 2026 | $12.7B | 87 5-pillar Nov 18, 2026 | |
| $551.33 Nov 19, 2026 | $7.15B | 85 5-pillar Nov 18, 2026 | |
| $62.10 Nov 19, 2026 | $9.48B | 59 5-pillar Nov 18, 2026 | |
| $20.95 Nov 18, 2026 | $7.49B | 35 5-pillar Nov 18, 2026 | |
| RadNet (RDNT) — this page | $69.51 | $5.48B | 34 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $65.00 – $95.00
- Consensus target
- $80.00
- Median target
- $80.00
Consensus record · Captured .
Measured against a quoted price of $69.51 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 11
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 5
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RDNT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RDNT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about RadNet (RDNT)?
Common Questions About RDNT (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is RadNet's primary source of revenue?
RadNet owns and operates outpatient imaging centers that perform MRI, CT, PET, mammography, and other diagnostic procedures. Revenue comes from per-procedure fees paid by insurance companies and self-pay patients.
Why would an investor prefer RadNet to hospital stocks?
RadNet operates purely on outpatient imaging with lower overhead than hospital-integrated centers. Profitability is more sensitive to payer rates and volume, but margins are typically higher than hospital radiology departments.
How concentrated is RadNet's revenue among major insurers?
RadNet contracts with multiple payers across commercial, Medicare, and Medicaid. Concentration risk exists with large regional or regional insurers, but no single customer appears to dominate revenue.
What would recession do to imaging procedure demand?
Elective procedures would likely decline as patients defer non-urgent care. Urgent diagnostic imaging would remain steady. The revenue hit would be significant unless RadNet offsets it with price increases or achieves better payer mix.
What is the RDNT stock price today?
The last price recorded for RadNet, Inc. (RDNT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RDNT price target?
The analyst consensus price target for RadNet, Inc. (RDNT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com